No Fed urgency leaves stocks at risk: JPMorgan

  • 📰 Investingcom
  • ⏱ Reading Time:
  • 44 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 21%
  • Publisher: 53%

Portugal Notícia Notícia

Portugal Últimas Notícias,Portugal Manchetes

No Fed urgency leaves stocks at risk: JPMorgan

JPMorgan analysts have raised concerns that the current equity market is increasingly a"two-sided debate," with risks stemming from potential growth downturns, uncertain Fed timing, and various geopolitical factors.

The bank explains that in the first half of the year, market attention was largely focused on the trajectory of inflation. However, the second half of the year is shifting attention to growth risks, particularly given the elevated earnings expectations for the latter half of 2024 and for 2025 . The current market pullback is seen as a reaction to fears of weakening growth and a reassessment of recession probabilities.

However, they conclude:"While the recent market flush took out some of the froth, equity positioning and valuation still remain at risk especially if growth continues to decelerate and the Fed does not show urgency."Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors.

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

 /  🏆 450. in PT
 

Obrigado pelo seu comentário. Seu comentário será publicado após ser revisado.

Portugal Últimas Notícias, Portugal Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

JPMorgan stock price at record high ahead of Q2 earningsJPMorgan earnings kick off earnings season on 12 July, but a slowdown is expected despite the stock’s run to record highs.
Fonte: DailyFX - 🏆 305. / 63 Consulte Mais informação »

Here are JPMorgan's top drug stock picks into earningsThese are JPMorgan's top drug picks heading into earnings.
Fonte: CNBC - 🏆 12. / 72 Consulte Mais informação »